Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial von BURRIS, H. A, MOORE, M. J, NELSON, R, DORR, F. A, STEPHENS, C. D, VON HOFF, D. D, ANDERSEN, J, GREEN, M. R, ROTHENBERG, M. L, MODIANO, M. R, CRIPPS, M. C, PORTENOY, R. K, STORNIOLO, A. M, TARASSOFF, P

Volltext

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer von STADLER, W. M, KUZEL, T, ROTH, B, RAGHAVAN, D, DORR, F. A

Volltext

Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease von Yacyshyn, B. R., Barish, C., Goff, J., Dalke, D., Gaspari, M., Yu, R., Tami, J., Dorr, F. A., Sewell, K. L.

Volltext

Potential antiproliferative activity of polyphenol metabolites against human breast cancer cells and their urine excretion pattern in healthy subjects following acute intake of a p... von Teixeira, L L, Costa, G R, Dörr, F A, Ong, T P, Pinto, E, Lajolo, F M, Hassimotto, N M A

Volltext

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer von McPhillips, F, Mullen, P, Monia, B P, Ritchie, A A, Dorr, F A, Smyth, J F, Langdon, S P

Volltext

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A) von STEVENSON, J. P, YAO, K.-S, DORR, F. A, O'DWYER, P. J, GALLAGHER, M, FRIEDLAND, D, MITCHELL, E. P, CASSELLA, A, MONIA, B, KWOH, T. J, YU, R, HOLMLUND, J

Volltext

Potential Role of Tamoxifen in Prevention of Breast Cancer von Nayfield, Susan G., Karp, Judith E., Ford, Leslie G., Dorr, F. Andrew, Kramer, Barnett S.

Volltext

Forced degradation study and characterization of main impurities of ibuprofen soft gelatin capsules by LC-MS-QTOF von Farias, F F, Martins, V A P, Dörr, F A, Trujillo, L M, Pinto, E

Volltext

A phase I evaluation of multitargeted antifolate (MTA, Ly231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation von RINALDI, D. A, KUHN, J. G, MASCORRO, D, ABRAHAMS, T, VON HOFF, D. D, BURRIS, H. A, DORR, F. A, RODRIGUEZ, G, ECKHARDT, S. G, JONES, S, WOODWORTH, J. R, BAKER, S, LANGLEY, C

Volltext

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation von RINALDI, D. A, BURRIS, H. A, CLARK, G, FARIES, D, LU, P, VON HOFF, D. D, DORR, F. A, WOODWORTH, J. R, KUHN, J. G, ECKARDT, J. R, RODRIGUEZ, G, CORSO, S. W, FIELDS, S. M, LANGLEY, C

Volltext

A metal-free blue chromophore derived from plant pigments von Freitas-Dörr, B C, Machado, C O, Pinheiro, A C, Fernandes, A B, Dörr, F A, Pinto, E, Lopes-Ferreira, M, Abdellah, M, Sá, J, Russo, L C, Forti, F L, Gonçalves, L C P, Bastos, E L

Volltext

c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A) von O'DWYER, P. J, STEVENSON, J. P, GALLAGHER, M, CASSELLA, A, VASILEVSKAYA, I, MONIA, B. P, HOIMLUND, J, DORR, F. A, YAO, K.-S

Volltext

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma von Crawford, E. David, Eisenberger, Mario A, McLeod, David G, Spaulding, Joseph T, Benson, Ralph, Dorr, F. Andrew, Blumenstein, Brent A, Davis, Marilyn A, Goodman, Phyllis J

Volltext

Tamoxifen and fenretinide in women with metastatic breast cancer von ZUJEWSKI, J, PAI, L, GOSSARD, M, NOONE, M. A, DENICOFF, A, VENZON, D, COWAN, K. H, O'SHAUGHNESSY, J. A, WAKEFIELD, L, GIUSTI, R, DORR, F. A, FLANDERS, C, CARUSO, R, KAISER, M, GOODMAN, L, MERINO, M

Volltext

Antisense Approaches for the Treatment of Cancer von Monia, Brett P., Holmlund, Jon, Dorr, F. Andrew

Volltext

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer von RUDIN, Charles M, HOLMLUND, Jon, KWOH, T. Jesse, DORR, F. Andrew, RATAIN, Mark J, FLEMING, Gini F, MANI, Sridhar, STADLER, Walter M, SCHUMM, Philip, MONIA, Brett P, JOHNSTON, Joseph F, GEARY, Richard, YU, Rosie Z

Volltext

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial von Burris, 3rd, H A, Moore, M J, Andersen, J, Green, M R, Rothenberg, M L, Modiano, M R, Cripps, M C, Portenoy, R K, Storniolo, A M, Tarassoff, P, Nelson, R, Dorr, F A, Stephens, C D, Von Hoff, D D

Volltext

Leuprolide With and Without Flutamide in Advanced Prostate Cancer von Crawford, E. David, Blumenstein, Brent A., Goodman, Phyllis J., Davis, Marilyn A., Eisenberger, Mario A., McLeod, David G., Spaulding, Joseph T., Benson, Ralph, Dorr, F. Andrew

Volltext

Metastatic bladder cancer: Advances in treatment von Stadler, W.M., Kuzel, T.M., Raghavan, D., Levine, E., Vogelzang, N.J., Roth, B., Dorr, F.A.

Volltext

Prognostic factors observed in current clinical trials von Dorr, F. Andrew

Volltext